DK1382343T3 - Kombinationsterapi til behandling af hepatitis B-virus - Google Patents

Kombinationsterapi til behandling af hepatitis B-virus

Info

Publication number
DK1382343T3
DK1382343T3 DK03077543.1T DK03077543T DK1382343T3 DK 1382343 T3 DK1382343 T3 DK 1382343T3 DK 03077543 T DK03077543 T DK 03077543T DK 1382343 T3 DK1382343 T3 DK 1382343T3
Authority
DK
Denmark
Prior art keywords
virus
combination
alternation
administering
directed
Prior art date
Application number
DK03077543.1T
Other languages
English (en)
Inventor
Phillip A Furman
George R Painter
David Barry
Franck Rousseau
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DK1382343T3 publication Critical patent/DK1382343T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DK03077543.1T 1998-11-02 1999-11-02 Kombinationsterapi til behandling af hepatitis B-virus DK1382343T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10666498P 1998-11-02 1998-11-02
EP99961553A EP1124562B1 (en) 1998-11-02 1999-11-02 Combination therapy to treat hepatitis b virus

Publications (1)

Publication Number Publication Date
DK1382343T3 true DK1382343T3 (da) 2010-04-26

Family

ID=22312611

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03077542T DK1380303T3 (da) 1998-11-02 1999-11-02 Kombinationsterapi til behandling af hepatitis B-virus
DK03077543.1T DK1382343T3 (da) 1998-11-02 1999-11-02 Kombinationsterapi til behandling af hepatitis B-virus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03077542T DK1380303T3 (da) 1998-11-02 1999-11-02 Kombinationsterapi til behandling af hepatitis B-virus

Country Status (16)

Country Link
US (3) US6528515B1 (da)
EP (3) EP1380303B1 (da)
JP (2) JP2002528508A (da)
KR (1) KR100632520B1 (da)
CN (3) CN1666742A (da)
AT (3) ATE408410T1 (da)
AU (1) AU1810600A (da)
CY (2) CY1108635T1 (da)
DE (3) DE69923338T2 (da)
DK (2) DK1380303T3 (da)
ES (3) ES2237189T3 (da)
HK (1) HK1062146A1 (da)
ID (1) ID29471A (da)
IL (3) IL142910A0 (da)
PT (2) PT1382343E (da)
WO (1) WO2000025797A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380303B1 (en) * 1998-11-02 2008-09-17 Gilead Sciences, Inc. Combination therapy to treat hepatitis B virus
AU2003246372B8 (en) * 2002-06-19 2009-03-26 Fideline Avian appeasing pheromones to decrease stress, anxiety and aggressiveness
WO2004006843A2 (en) * 2002-07-15 2004-01-22 Gilead Sciences, Inc. Combination therapies with l-fmau for the treatment of hepatitis b virus infection
EP3025718A1 (en) * 2003-01-14 2016-06-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
KR20100127180A (ko) * 2009-05-25 2010-12-03 부광약품 주식회사 클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물
CN102917706A (zh) * 2010-05-18 2013-02-06 富光药品株式会社 含有克拉夫定及阿德福韦酯的用于治疗慢性乙型肝炎的组合物
US9622967B2 (en) 2010-12-10 2017-04-18 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
CN107743491B (zh) * 2015-05-08 2020-08-21 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
CN105943547B (zh) * 2016-05-23 2018-01-19 北京慧宝源生物技术股份有限公司 抗hbv的药物组合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3485225D1 (de) * 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
JPH03501253A (ja) 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8904855D0 (en) * 1989-03-03 1989-04-12 Beecham Group Plc Pharmaceutical treatment
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5700937A (en) 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
WO1991018914A1 (en) 1990-05-29 1991-12-12 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
DK0533833T3 (da) 1990-06-13 1996-04-22 Arnold Glazier Phosphorprolægemidler
US5674869A (en) * 1990-07-07 1997-10-07 Beecham Group Plc Pharmaceutical treatment
US5674849A (en) 1990-10-24 1997-10-07 Allelix Biopharmaceuticals Inc. Anti-viral compositions
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5179104A (en) 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en) 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
JPH07500573A (ja) 1991-07-12 1995-01-19 ネクススター・ファーマシューティカルズ・インコーポレイテッド 抗ウィルス性リポヌクレオシド：ｂ型肝炎の治療
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
CA2162574A1 (en) 1993-05-12 1994-11-24 Karl Y. Hostetler Acyclovir derivatives for topical use
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
AU5127098A (en) * 1996-11-29 1998-06-22 Smithkline Beecham Plc Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
CN1196701C (zh) * 1997-03-19 2005-04-13 埃莫里大学 1,3－氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
EP1380303B1 (en) * 1998-11-02 2008-09-17 Gilead Sciences, Inc. Combination therapy to treat hepatitis B virus

Also Published As

Publication number Publication date
EP1124562A1 (en) 2001-08-22
DE69923338T2 (de) 2006-04-06
DE69939604D1 (de) 2008-10-30
IL142910A (en) 2009-06-15
KR100632520B1 (ko) 2006-10-09
IL193148A (en) 2011-09-27
PT1382343E (pt) 2010-03-10
PT1380303E (pt) 2008-11-03
ID29471A (id) 2001-08-30
ATE457734T1 (de) 2010-03-15
HK1062146A1 (en) 2004-10-21
KR20010082282A (ko) 2001-08-29
ES2314157T3 (es) 2009-03-16
ES2237189T3 (es) 2005-07-16
US20090247487A1 (en) 2009-10-01
EP1124562B1 (en) 2005-01-19
ATE408410T1 (de) 2008-10-15
CN1329497A (zh) 2002-01-02
US6528515B1 (en) 2003-03-04
EP1380303B1 (en) 2008-09-17
US7572800B2 (en) 2009-08-11
CY1108635T1 (el) 2014-04-09
IL193148A0 (en) 2009-02-11
CN1173705C (zh) 2004-11-03
AU1810600A (en) 2000-05-22
EP1382343B1 (en) 2010-02-17
IL142910A0 (en) 2002-04-21
EP1382343A1 (en) 2004-01-21
ATE287268T1 (de) 2005-02-15
US20030158150A1 (en) 2003-08-21
DE69942042D1 (de) 2010-04-01
CY1110629T1 (el) 2015-04-29
EP1380303A1 (en) 2004-01-14
DE69923338D1 (de) 2005-02-24
CN1891221A (zh) 2007-01-10
DK1380303T3 (da) 2008-12-01
JP2002528508A (ja) 2002-09-03
JP2011079840A (ja) 2011-04-21
CN1666742A (zh) 2005-09-14
ES2338642T3 (es) 2010-05-11
WO2000025797A1 (en) 2000-05-11

Similar Documents

Publication Publication Date Title
CY1110629T1 (el) Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β
YU96192A (sh) Trombin i postupak za njegovu proizvodnju
DE69233631D1 (de) 1,3-Oxathiolane zur Behandlung von Hepatitis
DK0665013T3 (da) Behandling af hyperproliferative karsygdomme
ATE395922T1 (de) Lipid-analoge zur behandlung von viralen infektionen
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DE69636734D1 (de) Nucleoside mit anti-hepatitis b virus wirksamkeit
ATE219838T1 (de) Verwendung von funktionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie
DE69932154D1 (de) Verwendung von n-substituirten-1,5-dideoxy-1,5-imino-d-glucitolen zur behandlung von hepatitis infektionen
BR9808221A (pt) Método de tratamento de tumor.
DE60123042D1 (de) L-fmau zur behandlung von hepatitis-delta-virus-infizierung
DE69921530D1 (de) Behandlung einer Virusinfektion bei Schweinen
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
FI945035A0 (fi) Pintasterilisointi laserkäsittelyn avulla
DE69006187T2 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.
EA200001065A1 (ru) Применение фосфорорганических соединений для терапевтического и профилактического лечения инфекций